| Vedolizumab as induction and maintenance therapy for ulcerative colitis BG Feagan, P Rutgeerts, BE Sands, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 699-710, 2013 | 2772 | 2013 |
| Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ... Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 1923 | 2015 |
| Tofacitinib as induction and maintenance therapy for ulcerative colitis WJ Sandborn, C Su, BE Sands, GR D’Haens, S Vermeire, S Schreiber, ... New England Journal of Medicine 376 (18), 1723-1736, 2017 | 1816 | 2017 |
| The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management A Dignass, G Van Assche, JO Lindsay, M Lémann, J Söderholm, ... Journal of Crohn's and Colitis 4 (1), 28-62, 2010 | 1785 | 2010 |
| STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD … D Turner, A Ricciuto, A Lewis, F D’amico, J Dhaliwal, AM Griffiths, ... Gastroenterology 160 (5), 1570-1583, 2021 | 1693 | 2021 |
| Epithelial NEMO links innate immunity to chronic intestinal inflammation A Nenci, C Becker, A Wullaert, R Gareus, G Van Loo, S Danese, M Huth, ... Nature 446 (7135), 557-561, 2007 | 1253 | 2007 |
| Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis R Panaccione, S Ghosh, S Middleton, JR Márquez, BB Scott, L Flint, ... Gastroenterology 146 (2), 392-400. e3, 2014 | 1109 | 2014 |
| Ustekinumab as induction and maintenance therapy for ulcerative colitis BE Sands, WJ Sandborn, R Panaccione, CD O’Brien, H Zhang, J Johanns, ... New England Journal of Medicine 381 (13), 1201-1214, 2019 | 1106 | 2019 |
| Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial J Panés, D García-Olmo, G Van Assche, JF Colombel, W Reinisch, ... The Lancet 388 (10051), 1281-1290, 2016 | 1074 | 2016 |
| Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial JF Colombel, R Panaccione, P Bossuyt, M Lukas, F Baert, T Vaňásek, ... The Lancet 390 (10114), 2779-2789, 2017 | 919 | 2017 |
| The safety of vedolizumab for ulcerative colitis and Crohn's disease JF Colombel, BE Sands, P Rutgeerts, W Sandborn, S Danese, G D'Haens, ... Gut 66 (5), 839-851, 2017 | 891 | 2017 |
| Crohn’s disease G Roda, S Chien Ng, PG Kotze, M Argollo, R Panaccione, A Spinelli, ... Nature Reviews Disease Primers 6 (1), 22, 2020 | 860 | 2020 |
| 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations P Gionchetti, A Dignass, S Danese, FJ Magro Dias, G Rogler, PL Lakatos, ... Journal of Crohn's and Colitis 11 (2), 135-149, 2017 | 826 | 2017 |
| Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease RM Gadaleta, KJ Van Erpecum, B Oldenburg, ECL Willemsen, W Renooij, ... Gut 60 (4), 463-472, 2011 | 799 | 2011 |
| Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management F D’amico, DC Baumgart, S Danese, L Peyrin-Biroulet Clinical Gastroenterology and hepatology 18 (8), 1663-1672, 2020 | 763 | 2020 |
| Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines J Panes, Y Bouhnik, W Reinisch, J Stoker, SA Taylor, DC Baumgart, ... Journal of Crohn's and Colitis 7 (7), 556-585, 2013 | 760 | 2013 |
| Development of the Crohn's disease digestive damage score, the Lémann score B Pariente, J Cosnes, S Danese, WJ Sandborn, M Lewin, JG Fletcher, ... Inflammatory bowel diseases 17 (6), 1415-1422, 2011 | 728 | 2011 |
| Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis BE Sands, L Peyrin-Biroulet, EV Loftus Jr, S Danese, JF Colombel, ... New England Journal of Medicine 381 (13), 1215-1226, 2019 | 704 | 2019 |
| Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses D Piovani, S Danese, L Peyrin-Biroulet, GK Nikolopoulos, T Lytras, ... Gastroenterology 157 (3), 647-659. e4, 2019 | 692 | 2019 |
| Tolerogenic dendritic cells: cytokine modulation comes of age S Rutella, S Danese, G Leone Blood 108 (5), 1435-1440, 2006 | 666 | 2006 |
